Institute for Chemical & Bioengineering, Department of Chemistry & Applied Biosciences, ETH Zürich, Vladimir-Prelog-Weg 1, 8093 Zürich, Switzerland.
Brain Research Institute, Medical Faculty of the University of Zürich, Winterthurerstrasse 190, 8057 Zürich, Switzerland.
ACS Sens. 2020 Sep 25;5(9):2701-2723. doi: 10.1021/acssensors.0c01488. Epub 2020 Sep 11.
Driven by complex and interconnected factors, including population growth, climate change, and geopolitics, infectious diseases represent one of the greatest healthcare challenges of the 21st century. Diagnostic technologies are the first line of defense in the fight against infectious disease, providing critical information to inform epidemiological models, track diseases, decide treatment choices, and ultimately prevent epidemics. The diagnosis of infectious disease at the genomic level using nucleic acid disease biomarkers has proven to be the most effective approach to date. Such methods rely heavily on enzymes to specifically amplify or detect nucleic acids in complex samples, and significant effort has been exerted to harness the power of enzymes for in vitro nucleic acid diagnostics. Unfortunately, significant challenges limit the potential of enzyme-assisted nucleic acid diagnostics, particularly when translating diagnostic technologies from the lab toward the point-of-use or point-of-care. Herein, we discuss the current state of the field and highlight cross-disciplinary efforts to solve the challenges associated with the successful deployment of this important class of diagnostics at or near the point-of-care.
受人口增长、气候变化和地缘政治等复杂且相互关联的因素驱动,传染病是 21 世纪最大的医疗保健挑战之一。诊断技术是对抗传染病的第一道防线,为流行病学模型提供关键信息,跟踪疾病,决定治疗选择,最终预防疫情。在基因组水平上使用核酸疾病生物标志物诊断传染病已被证明是迄今为止最有效的方法。这些方法严重依赖于酶来特异性地扩增或检测复杂样本中的核酸,并且已经付出了巨大的努力来利用酶的力量进行体外核酸诊断。不幸的是,重大挑战限制了酶辅助核酸诊断的潜力,尤其是在将诊断技术从实验室转化为即时或床边使用时。本文讨论了该领域的现状,并强调了跨学科的努力,以解决与成功部署这一重要类别的诊断技术在即时或床边使用相关的挑战。